Volume 19 Issue 9, September 2023

Biomarkers for Alzheimer disease can be measured from finger-prick blood samples, according to new findings presented at AAIC 2023.

The 2023 Alzheimer’s Association International Conference (AAIC) was held in Amsterdam, Netherlands on the 16–20 July 2023.

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and European Academy of Neurology (EAN) joint consensus statement on vaccination in people with multiple sclerosis provides highly relevant clinical guidance on immunization strategies in today’s era of effective immunotherapies. Nevertheless, several open questions remain to be addressed.

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease classically thought to impact the motor system, but research is now investigating the contribution of non-motor symptoms. Here, the authors explore evidence that highlights the extent to which nutrition and metabolism might contribute to ALS pathogenesis, and discuss the effectiveness of modifying energy balance in ALS.

Limbic-predominant age-related TDP43 encephalopathy (LATE) is a clinical entity characterized by amnestic dementia resembling Alzheimer disease. This Review focuses on the pathology, genetic risk factors and clinical features associated with pure LATE neuropathological change and LATE neuropathological change with coexisting pathologies.

The diagnosis of cerebral palsy is currently made on clinical observations only and does not consider aetiology or pathology. Here, van Eyk and colleagues review the current state of genomic testing in cerebral palsy and highlight the benefits of a ‘genotype-first’ approach for this group of disorders.

Understanding of the psychiatric and behavioural consequences of traumatic brain injury (TBI) remains limited. In this Review, Li and colleagues highlight ways to progress research in this field and discuss neuropsychiatric sequelae of TBI that affect long-term health outcomes and functional recovery.